- Home
- WERN vs DFTX Comparison
WERN vs DFTX Comparison
Compare WERN & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WERN | DFTX |
|---|---|---|
| Founded | 1956 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | WERN | DFTX |
|---|---|---|
| Price | $35.19 | $21.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $33.79 | ★ $38.50 |
| AVG Volume (30 Days) | 1.0M | ★ 1.9M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,974,396,000.00 | N/A |
| Revenue This Year | $22.24 | N/A |
| Revenue Next Year | $6.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.06 | $14.62 |
| 52 Week High | $38.52 | $26.25 |
Technical Indicators
Market Signals| Indicator | WERN | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.52 | 52.04 |
| Support Level | $30.30 | $16.37 |
| Resistance Level | $35.39 | $26.25 |
| Average True Range (ATR) | 1.24 | 1.19 |
| MACD | 0.03 | -0.14 |
| Stochastic Oscillator | 40.53 | 42.01 |
Price Performance
Historical ComparisonAbout WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company engaged in transporting truckload shipments of general commodities in both interstate and intrastate commerce. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About DFTX Definium Therapeutics Inc. Common Shares
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).